Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: Comparison with azosemide

Ken Harada, Hideo Izawa, Takao Nishizawa, Akihiro Hirashiki, Yosuke Murase, Masakazu Kobayashi, Satoshi Isobe, Wu Cheng Xian, Akiko Noda, Kohzo Nagata, Mitsuhiro Yokota, Toyoaki Murohara

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Loop diuretics could adversely influence prognosis due to activation of neurohumoral mechanism in the long term. Previous study showed torasemide, a loop diuretic with anti-aldosteronergic properties, was associated with lower mortality in patients with chronic heart failure (CHF). We evaluated the effects of torasemide, in comparison with azosemide, in patients with CHF. Patients received oral diuretic therapy with torasemide (8 mg/d, n = 15) or azosemide (60 mg/d, n = 15) for 3 months. Torasemide and azosemide were then switched, and the patients were treated for another 3 months. Torasemide treatment induced significant decreases in left ventricular (LV) systolic wall stress (from 259 ± 95 to 232 ± 80 kdyn/cm2) and the plasma level of aldosterone (from 133 ± 61 to 95 ± 50 pg/mL) and was not associated with a change in the plasma level of norepinephrine. In contrast, the plasma level of norepinephrine was significantly increased (from 370 ± 170 to 481 ± 247 pg/mL), whereas LV systolic wall stress was unchanged after azosemide treatment. This study indicates that torasemide treatment reduced LV systolic wall stress without activation of the sympathetic nervous system in patients with CHF. The anti-aldosteronergic properties of torasemide may contribute to its favorable effects.

Original languageEnglish
Pages (from-to)468-473
Number of pages6
JournalJournal of Cardiovascular Pharmacology
Volume53
Issue number6
DOIs
Publication statusPublished - 01-06-2009

Fingerprint

torsemide
Heart Failure
Sodium Potassium Chloride Symporter Inhibitors
Norepinephrine
Sympathetic Nervous System
Therapeutics
azosemide
Aldosterone
Diuretics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Harada, Ken ; Izawa, Hideo ; Nishizawa, Takao ; Hirashiki, Akihiro ; Murase, Yosuke ; Kobayashi, Masakazu ; Isobe, Satoshi ; Xian, Wu Cheng ; Noda, Akiko ; Nagata, Kohzo ; Yokota, Mitsuhiro ; Murohara, Toyoaki. / Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure : Comparison with azosemide. In: Journal of Cardiovascular Pharmacology. 2009 ; Vol. 53, No. 6. pp. 468-473.
@article{4fdd77104ed244118a9eb204c969c0f3,
title = "Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: Comparison with azosemide",
abstract = "Loop diuretics could adversely influence prognosis due to activation of neurohumoral mechanism in the long term. Previous study showed torasemide, a loop diuretic with anti-aldosteronergic properties, was associated with lower mortality in patients with chronic heart failure (CHF). We evaluated the effects of torasemide, in comparison with azosemide, in patients with CHF. Patients received oral diuretic therapy with torasemide (8 mg/d, n = 15) or azosemide (60 mg/d, n = 15) for 3 months. Torasemide and azosemide were then switched, and the patients were treated for another 3 months. Torasemide treatment induced significant decreases in left ventricular (LV) systolic wall stress (from 259 ± 95 to 232 ± 80 kdyn/cm2) and the plasma level of aldosterone (from 133 ± 61 to 95 ± 50 pg/mL) and was not associated with a change in the plasma level of norepinephrine. In contrast, the plasma level of norepinephrine was significantly increased (from 370 ± 170 to 481 ± 247 pg/mL), whereas LV systolic wall stress was unchanged after azosemide treatment. This study indicates that torasemide treatment reduced LV systolic wall stress without activation of the sympathetic nervous system in patients with CHF. The anti-aldosteronergic properties of torasemide may contribute to its favorable effects.",
author = "Ken Harada and Hideo Izawa and Takao Nishizawa and Akihiro Hirashiki and Yosuke Murase and Masakazu Kobayashi and Satoshi Isobe and Xian, {Wu Cheng} and Akiko Noda and Kohzo Nagata and Mitsuhiro Yokota and Toyoaki Murohara",
year = "2009",
month = "6",
day = "1",
doi = "10.1097/FJC.0b013e3181a717f7",
language = "English",
volume = "53",
pages = "468--473",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure : Comparison with azosemide. / Harada, Ken; Izawa, Hideo; Nishizawa, Takao; Hirashiki, Akihiro; Murase, Yosuke; Kobayashi, Masakazu; Isobe, Satoshi; Xian, Wu Cheng; Noda, Akiko; Nagata, Kohzo; Yokota, Mitsuhiro; Murohara, Toyoaki.

In: Journal of Cardiovascular Pharmacology, Vol. 53, No. 6, 01.06.2009, p. 468-473.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure

T2 - Comparison with azosemide

AU - Harada, Ken

AU - Izawa, Hideo

AU - Nishizawa, Takao

AU - Hirashiki, Akihiro

AU - Murase, Yosuke

AU - Kobayashi, Masakazu

AU - Isobe, Satoshi

AU - Xian, Wu Cheng

AU - Noda, Akiko

AU - Nagata, Kohzo

AU - Yokota, Mitsuhiro

AU - Murohara, Toyoaki

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Loop diuretics could adversely influence prognosis due to activation of neurohumoral mechanism in the long term. Previous study showed torasemide, a loop diuretic with anti-aldosteronergic properties, was associated with lower mortality in patients with chronic heart failure (CHF). We evaluated the effects of torasemide, in comparison with azosemide, in patients with CHF. Patients received oral diuretic therapy with torasemide (8 mg/d, n = 15) or azosemide (60 mg/d, n = 15) for 3 months. Torasemide and azosemide were then switched, and the patients were treated for another 3 months. Torasemide treatment induced significant decreases in left ventricular (LV) systolic wall stress (from 259 ± 95 to 232 ± 80 kdyn/cm2) and the plasma level of aldosterone (from 133 ± 61 to 95 ± 50 pg/mL) and was not associated with a change in the plasma level of norepinephrine. In contrast, the plasma level of norepinephrine was significantly increased (from 370 ± 170 to 481 ± 247 pg/mL), whereas LV systolic wall stress was unchanged after azosemide treatment. This study indicates that torasemide treatment reduced LV systolic wall stress without activation of the sympathetic nervous system in patients with CHF. The anti-aldosteronergic properties of torasemide may contribute to its favorable effects.

AB - Loop diuretics could adversely influence prognosis due to activation of neurohumoral mechanism in the long term. Previous study showed torasemide, a loop diuretic with anti-aldosteronergic properties, was associated with lower mortality in patients with chronic heart failure (CHF). We evaluated the effects of torasemide, in comparison with azosemide, in patients with CHF. Patients received oral diuretic therapy with torasemide (8 mg/d, n = 15) or azosemide (60 mg/d, n = 15) for 3 months. Torasemide and azosemide were then switched, and the patients were treated for another 3 months. Torasemide treatment induced significant decreases in left ventricular (LV) systolic wall stress (from 259 ± 95 to 232 ± 80 kdyn/cm2) and the plasma level of aldosterone (from 133 ± 61 to 95 ± 50 pg/mL) and was not associated with a change in the plasma level of norepinephrine. In contrast, the plasma level of norepinephrine was significantly increased (from 370 ± 170 to 481 ± 247 pg/mL), whereas LV systolic wall stress was unchanged after azosemide treatment. This study indicates that torasemide treatment reduced LV systolic wall stress without activation of the sympathetic nervous system in patients with CHF. The anti-aldosteronergic properties of torasemide may contribute to its favorable effects.

UR - http://www.scopus.com/inward/record.url?scp=68249124923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68249124923&partnerID=8YFLogxK

U2 - 10.1097/FJC.0b013e3181a717f7

DO - 10.1097/FJC.0b013e3181a717f7

M3 - Article

C2 - 19430310

AN - SCOPUS:68249124923

VL - 53

SP - 468

EP - 473

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 6

ER -